A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine
Kaashoek, M.J. ; Moerman, A. ; Madic, J. ; Rijsewijk, F.A.M. ; Quak, J. ; Gielkens, A.L.J. ; van Oirschot, J.T.
Amsterdam : Elsevier
Amsterdam : Elsevier
| ISSN: |
0264-410X
|
|---|---|
| Keywords: |
Bovine herpesvirus type 1 ; gE ; glycoprotein E ; marker vaccine
|
| Source: |
Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
|
| Topics: |
Medicine
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798291734071869440 |
|---|---|
| autor | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| autorsonst | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| book_url | http://dx.doi.org/10.1016/0264-410X(94)90122-8 |
| datenlieferant | nat_lic_papers |
| fussnote | We examined the vaccine properties of a conventionally attenuated bovine herpesvirus type 1 (BHV-1) mutant strain A. This strain has a deletion that encompasses the glycoprotein E gene and may therefore be used as a marker vaccine. We compared strain A with a commercial live BHV-1 vaccine B. Calves were intranasally vaccinated with strain A or with vaccine B. Strain A was virtually avirulent for young calves. After challenge, vaccinated calves were protected against disease and virus shedding was considerably reduced. After dexamethasone treatment, strain A was not recovered, whereas vaccine B and challenge virus were. We conclude that strain A is suitable for inclusion in a vaccine and has the potential advantage of being used as a marker vaccine. |
| hauptsatz | hsatz_simple |
| identnr | NLZ185514057 |
| issn | 0264-410X |
| journal_name | Vaccine |
| materialart | 1 |
| package_name | Elsevier |
| publikationsort | Amsterdam |
| publisher | Elsevier |
| reference | 12 (1994), S. 439-444 |
| schlagwort | Bovine herpesvirus type 1 gE glycoprotein E marker vaccine |
| search_space | articles |
| shingle_author_1 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| shingle_author_2 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| shingle_author_3 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| shingle_author_4 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. |
| shingle_catch_all_1 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine 0264-410X 0264410X Elsevier |
| shingle_catch_all_2 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine 0264-410X 0264410X Elsevier |
| shingle_catch_all_3 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine 0264-410X 0264410X Elsevier |
| shingle_catch_all_4 | Kaashoek, M.J. Moerman, A. Madic, J. Rijsewijk, F.A.M. Quak, J. Gielkens, A.L.J. van Oirschot, J.T. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine Bovine herpesvirus type 1 gE glycoprotein E marker vaccine 0264-410X 0264410X Elsevier |
| shingle_title_1 | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine |
| shingle_title_2 | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine |
| shingle_title_3 | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine |
| shingle_title_4 | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Elsevier Journal Backfiles on ScienceDirect 1907 - 2002 |
| timestamp | 2024-05-06T08:37:19.521Z |
| titel | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine |
| titel_suche | A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine We examined the vaccine properties of a conventionally attenuated bovine herpesvirus type 1 (BHV-1) mutant strain A. This strain has a deletion that encompasses the glycoprotein E gene and may therefore be used as a marker vaccine. We compared strain A with a commercial live BHV-1 vaccine B. Calves were intranasally vaccinated with strain A or with vaccine B. Strain A was virtually avirulent for young calves. After challenge, vaccinated calves were protected against disease and virus shedding was considerably reduced. After dexamethasone treatment, strain A was not recovered, whereas vaccine B and challenge virus were. We conclude that strain A is suitable for inclusion in a vaccine and has the potential advantage of being used as a marker vaccine. |
| topic | WW-YZ |
| uid | nat_lic_papers_NLZ185514057 |